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Abstract 
Metabolic hormones released from the gastrointestinal tract are core regulators for digestion, 
satiety, gut motility, and glucose homeostasis. Advancements in the management of type 2 
diabetes and obesity have recently included the use of incretin hormone-based therapies, such as 
glucagon-like peptide-1 (GLP-1) analogs. GLP-1 can enhance glucose-dependent insulin 
secretion and stimulate satiety after a meal. The release of this incretin is stimulated by the entry 
of nutrients in the lumen or circulation. In addition, microbial metabolites have recently emerged 
as a new group of potent stimulators of GLP-1 secretion. Hydrogen sulfide (H2S), produced from 
sulfate-reducing bacteria (SRB) of the distal ileum and colon, are localized in the same niche as 
GLP-1 secreting L-cells. The physiological role of endogenous H2S is well established in many 
biological systems, however it is not well understood how or if H2S can affect the 
enteroendocrine system. Therefore, we hypothesized that microbial H2S from the distal GI tract 
can potentially alter GLP-1 secretion and downstream metabolism, and further investigated the 
potential mechanisms involved in the process. In murine colonic L-cells (GLUTag), we 
demonstrated that H2S donors (NaHS and GYY4137) significantly enhanced GLP-1 secretion 
and that the process was regulated through the p38 MAPK signaling pathway. In male C57BL/6 
mice, a 4-week chondroitin sulfate prebiotic diet successfully elevated SRB and colonic H2S 
levels, enhanced the GLP-1 response, and reduced food intake. Together, this study 
demonstrated a direct role for H2S in the stimulation of GLP-1 and a potential role for sulfur 
prebiotics to increase the H2S producing SRB as a means to enhance GLP-1 and improve 
metabolism.  
Keywords: Diabetes, gut microbiome, glucagon-like peptide-1, metabolism, hormones  
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1. Introduction 
1.1 Gastrointestinal hormones & Metabolism 
The gastrointestinal (GI) tract is the passage beginning from the mouth, down the esophagus, 
into the stomach and intestines, and ending at the anus. The breakdown of food consumed is 
accomplished through the release of enzymes from accessory digestive organs, the contraction of 
muscles that propels the food (peristalsis) through the GI tract, and the action of GI hormones. 
Along the GI tract are various types of cells that sense the presence of nutrients in the GI lumen 
or in circulation. Among the cells of the intestinal epithelium, are enteroendocrine cells (EEC). 
Most EECs release hormones in response to food-related stimuli, which govern metabolic 
processes that include digestion, glucose control, satiety, and gut motility (1,2). These particular 
EECs have direct contact with the luminal contents through their microvilli-covered apical 
surfaces (3,4). Once stimulated, hormone-containing granules are exocytosed through the 
basolateral membrane and into the connecting capillary network of the lamina propria, or they 
may act locally on surrounding cells (5). Hormones can act directly on tissues/organs, or they 
may bind to receptors on neurons that can send metabolic information to the central and 
peripheral nervous system (5). The rate and quantity of GI hormones released are determined by 
patterns of meal intake, the type of nutrient stimuli, and the localization of the endocrine cell (1). 
Generally, gut hormone levels increase after a meal, however ghrelin and somatostatin are some 
of the exceptions that peak before meals (6). Table 1 highlights many of the key gut hormones, 
their localization, and their main physiological roles in humans (although there could be many 
secondary sites of synthesis and effect).   
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Table 1. Key metabolic hormones (Adapted from (1)) 
Enteroendocrine 
Cell Type 
Cell 
Localization 
Major 
hormone 
released 
Main function 
L-cell Ileum, colon GLP-1 • Incretin effect 
• Appetite control 
• Gut motility 
GLP-2 • Enterocyte growth 
• Enhance intestinal 
function/blood flow 
PYY • Water/electrolyte 
regulation 
• Appetite regulation 
K-cell Duodenum, 
jejunum 
GIP • Incretin effect 
• Inhibit gastric 
secretion/motility 
G-cell Stomach, 
duodenum 
Gastrin • Acid secretion 
• Gut motility 
S-cell Duodenum,  
Jejunum 
Secretin • Water regulation 
• Bicarbonate secretion 
I-cell Duodenum, 
jejunum 
CCK • Gall bladder secretion 
• Pancreatic enzyme 
secretion 
• Appetite control 
P/D1 cell/Epsilon 
cells 
(P/D1 cells in 
Stomach) 
(Epsilon cells in 
pancreas) 
Ghrelin • Appetite control 
• Growth hormone 
secretagogue 
• Energy balance 
Adipose tissue Leptin • Appetite control 
• Energy balance 
Alpha-cell Pancreas Glucagon • Conversion of glycogen 
into glucose 
• Inhibits glycolysis 
Beta-cell Pancreas Insulin • Glucose, carbohydrate, 
fats, and protein uptake in 
tissues 
(metabolism/storage) 
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1.2 Insulin stimulating GI hormones: Incretins 
Insulin is well known for its essential metabolic role in the reduction of blood glucose. Insulin is 
released from the beta cells of the pancreas, and promotes the uptake of glucose and its 
conversion into glycogen in tissues, and halts the glucose production from the liver (7). Inversely 
to the effect of insulin, glucagon increases the hepatic glucose output and stimulates the 
breakdown of glycogen into glucose (8). Diabetes mellitus encompasses the metabolic disorders 
(microvascular and macrovascular diseases) caused by long-term exposure to high circulating 
glucose (9). This can occur from a dysfunction of insulin secretion (Type 1), tissues becoming 
unresponsive to insulin’s function, termed insulin resistance (Type 2), or an insulin resistance 
developed during pregnancy due to hormonal changes (Gestational)(9). The development of 
insulin analogs (molecules that mimic insulin action) or insulin secretagogues (molecules that 
enhance insulin release) are the cornerstones of managing the many forms of diabetes. 
There are many factors and regulators involved in the control of insulin secretion. Beta cells can 
sense changes in concentration of glucose and other nutrients in circulation, and will release 
insulin based on these rising levels (7). Insulin secretion can also be enhanced through incretin-
dependent mechanisms (10). Incretins are GI hormones that are released post-prandially (after a 
meal) from EECs such as L-cells and K cells. These hormones travel in circulation to the 
pancreas where they can bind directly to surface receptors of beta cells and enhance glucose-
stimulated insulin secretion (10).  There are 2 incretin hormones: Glucagon-like Peptide-1 (GLP-
1, from the L-cell) and Gastric Inhibitory Peptide (GIP, from the K cell) (10).  
K cells are found in the crypts (invaginations) of the duodenum and jejunum (10,11). GIP is a 42 
amino acid incretin, that  also has a secondary role of inhibiting acid secretion from the stomach 
(12–14). The regulation of GIP is mainly through the entry of nutrients in the duodenum, 
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although neural stimulation by the vagus nerve has been suggested to be involved as well (15). 
Some of these nutrient stimuli include carbohydrates, glucose, lipids, amino acids, and long-
chain fatty acids (4,10,16–19). Postprandial GIP levels peak between 10-20 min after food 
ingestion (16,18–20). While both GIP and GLP-1 are able to enhance insulin secretion, more 
attention has been given to GLP-1, as it has had greater therapeutic value in the treatment of type 
2 diabetes mellitus (T2DM) (21–25).  
GLP-1 is derived from the cleavage of proglucagon (a pro-hormone) by proteases in the L-cell, 
where there are more abundantly located in the ileum and colon (26,27)(Fig. 1). An N-terminal 
cleavage of proglucagon liberates glicentin (28), which can be further cleaved into 
oxyntomodulin and glicentin-related pancreatic polypeptide (GRPP) (29,30). A C-terminal 
cleavage liberates GLP-2, and the middle portion can be truncated to form GLP-1 (31,32). GLP-
1 exists in two major forms in circulation: GLP-11-37, and a truncated GLP-17-37 that is more 
abundant and potent (32,33). Alpha cells from the pancreas can also produce small quantities of 
GLP-1 from the cleavage of proglucagon by proprotein convertases expressed in pancreatic 
islets. Alpha cells are interspread with beta cells, therefore, studies discussing the local alpha cell 
GLP-1 release describe a paracrine role for GLP-1 on beta cell regeneration (34). Rat and human 
islets produce small quantities of GLP-1 (~3.5 fmol/islet) (34), however picomolar 
concentrations of GLP-1 are required to activate the GLP-1R on islet beta cells to increase 
insulin secretion (35). The mechanisms of GLP-1 release from the alpha cell and L-cell are 
different, therefore, this study will focus on the L-cell derived GLP-1 release.  
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 Figure 1. Proglucagon posttranslational processing (Adapted from (36)). 
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1.3 Mechanisms of GLP-1 secretion and action on the pancreas 
There are two phases of postprandial GLP-1 release: the initial secretion within 15 min of food 
intake, and a second phase that occurs later in digestion after 90 – 120 min (37). L-cells are 
located in the distal small intestine of humans and rodents (38), therefore the initial GLP-1 
release is proposed to be stemming from neural stimulation, and the later secretion from luminal 
or circulating nutrients binding directly to the cell’s surface receptors (39). Nutrients including 
fatty acids, glucose, and bile acids can bind to their respective receptors on the L-cell and 
stimulate the release of GLP-1 vesicles by activating certain intracellular pathways (Fig 2). 
1) Short chain fatty acids (SCFAs) from microbial fermentation and medium/long chain 
fatty acids (MCFAs and LSCFAs) from the breakdown of food can bind to fatty acid 
receptors on the surface of the L-cell. These nutrient receptors have been identified as 
GPR120 (40), GPR119 (41), GPR40 (42), and GPR41(43,44), and GPR43(43).  Fatty 
acids binding to their receptor results in an elevation of intracellular Ca2+ ions, and the 
subsequent activation of a Ca2+-sensitive transient receptor potential channel M5 
(TRPM5) (40,42). TRMP5 stimulates the entry of Na+ ions, causing a membrane 
depolarization and the release of GLP-1 vesicles from the cell. 
2) L-cells also express sweet taste receptors that can respond to various sweet molecules 
including natural sugars, sweeteners, and sweet proteins (45). These receptors can recruit 
sodium glucose cotransporters (SGLT-1), that can uptake the monosaccharide coupled to 
a Na+ ion into the L-cell (46). Once the monosaccharide is metabolized into ATP, the 
resulting energy triggers the ATP-sensitive potassium (KATP) channel. The KATP channel 
allows the entry of K+ ions and release of Na+ ions, causing the membrane to depolarize. 
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L-type calcium channels are activated from the depolarization, and allow an influx of 
Ca2+ ions and the subsequent exocytosis of GLP-1 vesicles (47). 
3) Bile acid is another well-established stimulus of GLP-1 secretion (48). L-cells express a 
G protein-coupled bile acid receptor GPBAR1(TGR5) and a nuclear receptor farnesoid X 
receptor (FXR) (49). Once activated, these induce an elevation of intracellular cyclic 
adenosine monophosphate (cAMP). Similarly to the previous two nutrient-stimulating 
pathways, cAMP causes a rise in Ca2+ ions, and the subsequent secretion of GLP-1 
vesicles (49). 
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Figure 2. Intracellular mechanisms of GLP-1 secretion within the L-cell (Adapted from 
(50)) 
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Once GLP-1 is released from the L-cell it may enter the lamina propria and diffuse into the 
capillaries. Circulating GLP-1 level can be regulated by the enzymatic activity of dipeptidyl 
peptidase IV (DPPIV) (51,52). In the context of insulin secretion, GLP-1 binds directly to the 
GLP-1 receptor on the surface of the beta cell and causes the release of its insulin vesicles. G 
protein coupled receptor activation leads to the activation of adenylate cyclase, the elevation of 
cAMP, the activation of protein kinase A (PKA), and cAMP-regulated guanine nucleotide 
exchange factor II (Epac2) (10,53). Similar to glucose, GLP-1 acts by closing the KATP channel, 
causing the membrane to depolarize and an influx of Ca2+ ions (53). The rise of Ca2+ ions will 
stimulate the exocytosis of insulin vesicles into circulation (53).  
This peptide also possesses many other  metabolic functions that include slowing gastric 
emptying (how quickly food leaves the stomach) to induce satiety, and reducing glucagon release 
from  the alpha cells (54–56).  Therefore, GLP-1 has an essential role to play in the treatment of 
T2DM and more recently discovered obesity. GLP-1 agonists such as Exenatide 
(Byetta/Bydureon) and Liraglutide (Victoza/Saxenda) are currently on the market as non-
insulinic options for T2DM. Many studies have administered Liraglutide (57–61) and Exenatide 
(62,63) at different doses, and have shown significant glycemic benefits in both rodents and 
humans. These products have many advantages for T2DM patients: they can be taken in 
combination with insulin medication, do not have any risks of causing hypoglycemia, and have 
been shown to help the patient lose weight. Recently, Liraglutide has been approved as a 
treatment for obesity in Canada. The role of GLP-1 in food intake and obesity will be reviewed 
in the subsequent section.  
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1.3 GLP-1’s action in the brain 
Mechanoreceptors and chemoreceptors dispersed along the GI tract can detect the entry of food 
and nutrients, and signal the information through the vagus nerve to the brain (Reviewed in 
(64)). However, GI hormones such as GLP-1 are also essential appetite regulators. Because 
GLP-1 has a short half-life in circulation, it has been suggested that this peptide binds to 
peripheral receptors on the vagal nerve (65) and transmits metabolic information to the nucleus 
tractus solitarius (NTS) in the brainstem (66–70), which then signals the hypothalamic 
nuclei(66,71). However, the complete mechanism involving GLP-1 and satiety is not completely 
understood. 
There are other hormones that can also play a role in hunger and food intake, including peptide 
tyrosine tyrosine (PYY), leptin, ghrelin, and others. However, GLP-1 is the only GI hormone to 
have an approved analog used for weight loss. Liraglutide (marketed under Saxenda in Canada) 
has become an attractive medication for T2DM because of its secondary effect of weight loss, as 
previously mentioned.   
In summary, digestion, glycaemia, and food intake are all regulated in part by gut hormones like 
GLP-1. The entry of nutrients in the GI tract, dispersed peripheral neurons, and other hormones 
may regulate the secretion of GLP-1. Because GLP-1 is a key player of insulin secretion and 
core to the progression of T2DM, there is an important need in diabetes research on other ways 
GLP-1 levels can be enhanced. The intestinal microbiota has recently emerged as an important 
contributor to our metabolism and many biological functions.   
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1.4 Gut Microbiota & Metabolism 
Among the diverse community of EECs that are dispersed throughout our GI tract, lives another 
important cellular community: the gut microbiome. The human colonic microflora is composed 
of thousands of species, however, each individual’s microbial community interpersonally differs 
from another (72). Only approximately 160 species are conserved throughout each individual as 
a core gut microbiome (72). As reviewed in (73), the gut microbiota contribute to many essential 
processes including: complementing mammalian enzymes in the breakdown of non-digested 
material, protecting from the entry of pathogens, stimulating the immune system, and eliminating 
toxins. Also reviewed in (74),  a potential role of this gut community on human health has been 
demonstrated in a variety of studies comparing the fecal microbiota of healthy individuals to 
patients with obesity, diabetes, inflammatory bowel disease (IBD), irritable bowel syndrome 
(IBS), colon cancers, and others (75).  
The gut microbiome emerged in obesity research due to differences of microbial composition 
between obese and lean individuals. One of the first major studies examining these microbial 
differences used a genetic model of obesity (ob/ob) in mice, and observed different cecal 
bacterial communities between obese and lean wild type (76). Further investigation revealed that 
bacteria specialized in energy extraction were more abundant in the ob/ob mice than in the lean 
group. These results suggested that the composition of the microbiota can promote or resist 
obesity in these mice (76). Another important study confirming the relationship between bacteria 
and obesity was one that inoculated germ-free mice (GF) with the luminal contents of lean or 
obese mice (77). GF mice that received the microbiota from obese donors gained more weight 
than the lean group, with equivalent food intake. GF mice are also resistant to diet-induced 
obesity and are significantly leaner than conventional mice. Differences in obese and lean 
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individual microbial communities were also examined in humans, and further studies determined 
diet interventions can shape and specialize the bacterial community (78). Recent research has 
also demonstrated that the obese microbiome has a depletion of the phylum of Bacteroidetes, a 
reduction of overall bacterial diversity, and species specialized in carbohydrate and lipid-
utilization (79).  
Therefore, the composition of the gut microbiota may predispose an individual to obesity, and 
contribute to it with enhanced absorption of lipids and carbohydrates. However, what 
mechanisms link the microbiome to obesity and other metabolic complications?  
1.5 Bacterial metabolites 
Bacteria in the GI tract metabolize undigested host derived dietary components for their own 
metabolic needs (Reviewed in (80)). The small intestine of humans is capable of digesting 
approximately 90% of proteins/carbohydrates (81–84), while the rest are left to bacterial 
degradation . Although the stomach and small intestine are efficient in their digestion, a 
significant portion of these compounds may reach the large intestine where the microbiota is 
most abundant (84,85). Microbial metabolites are the resulting by-products of the breakdown of 
these undigested materials, where the highest microbial activity and accumulation of metabolites 
can be seen in the large intestine. As previously described, EECs are dispersed throughout the GI 
tract and can come into contact with these products. A review by Neuman et al. (86) has 
described how some gut bacteria and their metabolites can alter the endocrine system, however 
this introduction will focus specifically on the crosstalk between L-cells and potential microbial 
metabolites.  
Several recent studies have suggested that the presence or absence of certain microbial groups 
can alter GLP-1 release. GF and antibiotic treated mice have elevated GLP-1 levels (87).  
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Probiotics containing butyrate-producing bacteria given to mice also increased GLP-1 level (88). 
Beneficial increases of GLP-1 levels in rats (89) and humans (90) have also been correlated with 
changes in the composition of the intestinal microbiota. Many other bacterial metabolites are 
present in the gut from colonic microbial metabolism, including polyphenols, secondary bile 
acids, and microbial gases (91). However, relatively little is known on the mechanisms behind 
metabolite-induced GLP-1 secretion.  
Microbial gases are largely produced in the colon, and these include hydrogen (H2), hydrogen 
sulfide (H2S), and methane (CH4). Hydrogenotrophs include members like sulfate reducers, 
methanogens, and acetogens that compete for the hydrogen to use for their own metabolism 
(Reviewed in (92)). The existence of these bacteria are essential to the proliferation of other gut 
microbiota members because the accumulation of protons (produced by fermentative bacteria) 
can limit or be detrimental to the growth of the gut microflora (Reviewed in (92)). Hydrogen is 
cross-fed between species and reduced to hydrogen sulfide or methane. The resulting gas from 
these bacterial metabolic processes are released through the lungs, flatus, or absorbed in the 
colonic tissue (92). Healthy humans can produce liters of gas per day, therefore it is likely these 
gases can reach high concentrations in the lumen of the colon (93).  
1.6 Sulfate-reducing bacteria and hydrogen sulfide 
Sulfate-reducing bacteria (SRB) are the main bacterial producers of H2S in the intestine (94). 
SRB are obligate anaerobic bacteria and belong to a few taxonomic groups under the δ-
Proteobacteria phylum, namely: gram-negative mesophilic SRB, Gram-positive spore-forming 
SRB, bacterial thermophilic SRB, and archaeal thermophilic SRB (95) . SRB use dissimilatory 
sulfate reduction, a form of anaerobic respiration that uses sulfate as the electron acceptor and 
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hydrogen (or organic compounds) as electron donors to synthesize H2S (96,97). This reaction is 
summarized as followed:  
4𝐻𝐻2 + 𝑆𝑆𝑂𝑂42− + 𝐻𝐻+ → 𝑯𝑯𝑯𝑯− +  4𝐻𝐻2𝑂𝑂 
Sulfate may be provided by the host through an inorganic source (i.e. sulfite, sulfates) or organic 
sources (i.e. sulfated mucins or dietary intake) (94). High levels of H2S can be toxic, however the 
colonic tissues contain efficient detoxifying enzymes and storage mechanisms to eliminate H2S 
before it is released from the body (98).  The concentration of H2S in the lumen varies depending 
on substrate (sulfate) availability, and the abundance/activity of SRB.  H2S is also produced 
ubiquitously in many other tissues through non-microbial processes (endogenous H2S), and 
many studies have examined its physiological importance in other systems, as thoroughly 
reviewed by (99). The known and potential roles of H2S in GI hormone regulation and 
downstream glucose homeostasis and diabetes are presented in the subsequent review article.  
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Abstract 
Diabetes and its co-morbidities continue to be a major health problem worldwide. Understanding 
the precise mechanisms that control glucose homeostasis, and their dysregulation during 
diabetes, are a major research focus. Hydrogen sulfide (H2S) has emerged as an important 
regulator of glucose homeostasis. This is achieved through its production and action in several 
metabolic and hormone producing organs including the pancreas, liver, and adipose. Of 
importance, H2S production and signaling in these tissues is altered during both type 1 and type 2 
diabetes mellitus.  This review first examines how H2S is produced both endogenously and by 
gastrointestinal microbes, with a particular focus on the altered production that occurs during 
obesity and diabetes. Next, the action of H2S on the metabolic organs with key roles in glucose 
homeostasis, with a particular focus on insulin, is described.  Recent work has also suggested 
that the effects of H2S on glucose homeostasis go beyond its role in insulin secretion. Several 
studies have demonstrated important roles for H2S in hepatic glucose output and adipose glucose 
uptake. The mechanisms of H2S's actions on these metabolic organs are described. In the final 
part of this review, future directions examining the roles of H2S in other metabolic and 
glucoregulatory hormone secreting tissues are proposed.    
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Introduction 
Hydrogen sulfide (H2S) is a colorless gas that is produced both endogenously by a variety 
of mammalian cells and by the sulfate-reducing bacteria in the lower gastrointestinal tract. H2S 
has emerged as an important gasotransmitter that regulates several systems including the 
cardiovascular, GI, immune, endocrine, and nervous systems (reviewed in detail in (99)). One 
area of recent interest is the potential role that H2S may play in glucose regulation and metabolic 
health. Indeed, several groups have demonstrated that H2S levels are altered obese and diabetic 
circulation  (100,101) and tissues (102,103). The precise mechanisms of how H2S can drive 
metabolic changes are beginning to be understood. A major factor in the regulation of glucose 
metabolism is the secretion and action of metabolic hormones. These hormones include insulin, 
glucagon, leptin and Glucagon like peptide-1 to name a few. Several groups have already 
described the action of H2S on insulin secretion (104–106). Furthermore, recent work has 
demonstrated the effects of H2S on downstream hormone signaling action (107). These studies, 
and others, suggest that H2S may be a potential target in the treatment of metabolic diseases 
through modulating metabolic hormone secretion and signaling. The goal of this review is to 
describe the roles of H2S in the regulation of metabolic hormone secretion, with a particular 
focus on insulin, and the downstream signaling of these hormones in the regulation of energy 
homeostasis.   
 
 H2S Production  
Although the presence of H2S in the body has been known for some time, the precise locations of 
its production remain an active area of research. H2S is produced by a large variety of cell types 
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in the body (here named endogenous) and by host microbes including the sulfate-reducing 
bacteria in the GI tract. The main enzymatic machineries in the endogenous production of H2S 
are the cystathionine metabolizing cystathionine-β-synthase (CBS) (108) and cysthanionine ƴ-
lyase (CSE)(109). Other enzymes such as 3-mercaptopyruvate sulfurtransferase (MST) and 
cysteine aminotransferase (CAT) are also important in specific tissue types (110). CSE activity is 
much higher than CBS in peripheral tissues, while CBS mainly predominates in the brain  
(111,112). The precise mechanisms involving the production of endogenous H2S are thoroughly 
reviewed by Wang in (99). Once H2S is produced in the cell, it can act on different cellular 
pathways or be stored for later release. H2S can store its sulfur group with iron (acid labile 
sulfur) (113) or in sulfane sulfur (a persulfide)(114) in mammalian tissues. When required, and 
under the appropriate conditions, this bound sulfur can be released as S2-, HS-, or H2S (115).  
In addition to endogenous generation, H2S can be produced from microorganisms in the GI tract. 
The gut microbiota aids in the decomposition and harvest of nutrients from food, a crucial step in 
energy production. Primary fermenters break down protein and complex carbohydrates into 
short-chain fatty acids (e.g., acetate, proprionate, and butyrate) that are an important energy 
source, and gases (e.g., hydrogen, carbon dioxide) that are released or absorbed by the system. 
Hydrogenotrophs, or H2-consuming bacteria, are essential in keeping luminal hydrogen levels 
low, and stabilizing the environment for these primary fermenters. Among the groups of 
hydrogenotrophs are methanogens (produce methane), acetogens (produce acetate), and sulfate-
reducing bacteria (produce H2S). Sulfate reducing bacteria use hydrogen or organic compounds 
as electron donors and use sulfate as their terminal electron acceptor leading to a large 
production of H2S. This process is known as dissimilatory sulfate and can lead to mM 
concentrations of H2S in the lumen (116). Sulfur sources from diet can originate from amino 
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acids, preservatives, food additives (carrageenan), or as dietary supplements (chondroitin 
sulfate)(116). Microbial produced H2S is a significant contributor to the bodies H2S pool, as 
germ free mice have between 50-80% less H2S in their tissues and circulation (117). Microbial 
H2S has been associated with both maintaining gastric health, and being implicated in disease. 
Several groups have shown that H2S regulates various physiological functions including 
maintenance of GI barrier function and injury repair (118). Some earlier studies have suggested 
that H2S may be involved in the etiology of ulcerative colitis (119). However, more recent work 
points towards a protective role(120). Regardless of its source, H2S has emerged as a regulator of 
glucose metabolism. The mechanisms of this action are described below. 
 
Importance of H2S in diabetes and insulin regulation 
Insulin is one of the most researched, and clinically important, of the metabolic hormones. 
Strategies that seek to enhance insulin secretion and sensitivity are the cornerstone of diabetes 
treatment. Insulin biosynthesis is regulated by many physiological events, however the main 
driver of its secretion is circulating glucose, such that after a meal is consumed, the levels of 
insulin spike in circulation. Insulin then acts on a variety of tissues in the body, including, but not 
limited to, adipose, liver, and muscle. The cells are activated through the insulin receptor which 
then leads to increased translocation of glucose transporters to the membrane and glucose uptake. 
During the development of type 2 diabetes mellitus (T2DM), insulin signaling in the target 
tissues is impaired, and in order to overcome this resistance, the β-cells of the pancreas begin to 
proliferate and produce more insulin. In cases where the pancreas is unable to produce sufficient 
insulin to regulate the rising glucose levels, T2DM develops. In this scenario, a variety of 
treatments that act to increase insulin levels or enhance insulin signaling are employed. 
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Nevertheless, additional strategies to enhance insulin levels and signaling are of great interest in 
the treatment of diabetes and metabolic disease. 
 The investigation of hydrogen sulfide’s potential involvement in glucose metabolism began in 
1990 when Hayden and colleagues showed that a low dose (75ppm) H2S exposure increased 
circulating glucose in postpartum rats (121). Later on, several groups began to investigate how 
H2S levels fluctuate in metabolic disease. Human studies that have examined circulating H2S in 
T2DM have found them to be reduced. Jain and colleagues found that T2DM individuals had 
significantly lower H2S compared to age matched non diabetics (100). Whiteman and colleagues 
confirmed these findings and further demonstrated that adiposity was negatively correlated with 
H2S (101). This is of particular interest since obesity is one of the principal causes of T2DM. 
Unfortunately, the mechanisms driving these changes in circulating H2S or their effects on 
glucose metabolism were not investigated. As such, it is unclear whether the altered circulating 
H2S observed in obese individuals is a driving force in their metabolic disease. A more 
mechanistic understanding of how H2S can alter glucose metabolism has come to light through 
the examination of glucoregulatory hormones such as insulin and its target tissues. These 
pathways and their role in glucose homeostasis are described below. 
 
H2S production and function in the pancreas 
The first evidence that H2S was produced in the pancreas, and that it played a role in the 
regulation of insulin secretion, came from Yang and colleagues. Using the INS-1 cell line, they 
demonstrated that β cells express the enzymatic machinery required to produce H2S, including 
CSE, and can produce high levels of H2S which blocks glucose-stimulated insulin secretion 
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(106). This was later confirmed in another β cell model, Min6 (122). Yang and colleagues also 
demonstrated that treating INS-1 cells with H2S, or overexpressing CSE, stimulated apoptosis 
(105). In addition, other groups have demonstrated the mRNA expression of both CSE and CBS 
in the rat pancreas, and that streptozocin-induced diabetes (a model of type 1 diabetes) causes 
increased mRNA expression of CBS and increased H2S production  (102). Using a rodent model 
of obese diabetic (the Zucker diabetic fatty rat), Wu and colleagues demonstrated that the 
animals impaired glucose metabolism was due to an overproduction of pancreatic H2S and 
impaired insulin secretion (104). Together, these studies suggest that increases in H2S may be 
responsible for a reduction in insulin secretion and ultimately the impaired glucose clearance that 
occurs in diabetes. However, other groups have suggested that the elevated H2S production from 
the β cell is occurring as a result of elevated circulating glucose, and that H2S is acting as a 
pancreatic brake, which may protect these insulin producing cells from being over stimulated by 
chronic hyperglycemia (123). Indeed, it was later demonstrated that mice on a high fat diet 
lacking CSE have significantly worse islet glucotoxicity compared WT animals (124). This 
protective role for H2S in β cell apoptosis occurs through H2S mediated activation of thioredoxin, 
a system responsible for controlling redox homeostasis that protects β-cells from glucotoxicity. 
The difference in reports of the protective vs toxic effect of H2S in the pancreas may be due to 
the cell/animal model being used (whole animal vs cell studies, and type 1 vs type 2 diabetes 
models). Nevertheless, H2S is produced in the pancreas and this appears to have important 
implications in insulin secretion and glucose homeostasis. How this gasotransmitter can elicit its 
effects on the cell is discussed below. 
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Mechanism of H2S action in the pancreas 
The earliest reports on the intracellular target of H2S in insulin regulation was found to be an 
opening of the KATP channel  (106). When glucose enters the β-cell, it generates ATP, causing 
the closure of ATP sensitive KATP channels and opening of calcium channels leading to 
depolarization, and thus insulin secretion  (125). When KATP channels are kept open by H2S, the 
β cell is hyperpolarized and insulin secretion is suppressed. Based on this, several groups have 
demonstrated that compounds that suppress the production of H2S can increase the secretion of 
insulin from β cells (106,122). The precise mechanisms involved the opening of this channel 
remains an active area of research. It has been suggested that direct binding of H2S to cysteine 
residues in proteins (sulfhydration) may be a potential mechanism  (126). Using the patch clamp 
method coupled with channel subunit mutagenesis, Jiang and colleagues demonstrated the 
importance of the rvKir6.1/rvSUR1 subunits in mediating KATP channel opening (127). It should 
be noted however that the above studies on the precise mechanisms of H2S on the KATP have not 
been done in the β cell. 
Voltage-dependent calcium channels (VDCCs) in the β-cells control the movement of calcium, a 
crucial step in glucose stimulated insulin release. One of the early studies examining the effect of 
H2S in β-cells found that NaHS (an H2S donor) caused a decrease in the calcium oscillations 
caused by glucose, which ultimately led to reduced insulin secretion  (122). Using whole mouse 
islets, Tang and colleagues demonstrated (via patch clamp) that L-type VDCC current density is 
inhibited by the H2S donor NaHS, and that islets from mice lacking CSE had reduced L type 
VDCC activity (127).  Of interest, these reports of decreased VDCC activity in β-cells and islets 
are in contrast to the increased calcium concentrations that result from H2S in cerebellar granule 
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neurons  (128). This difference suggests that H2S may regulate similar intracellular pathways in 
distinct manners depending on the cell type. 
In addition to ion channel activities, H2S may also regulate insulin secretion through the 
modulation of intracellular kinases. Several of these kinases are known to be modulated during 
the secretion of insulin and other hormones including PI3K, ERK, AKT and MAPK. H2S 
mediated suppression of insulin secretion has been shown to cause phosphorylation of p38 
MAPK (105). Indeed, activation of the MAPK/JNK pathway is a known mechanism of impaired 
insulin release from the β cell (129). More studies are required to determine if additional cell 
signaling pathways are altered through the activity of H2S. 
 
H2S effects on metabolic tissues 
The description thus far focused on the production and effects of H2S in the insulin secreting β 
cell. A vital part of glucose homeostasis is the function of the insulin sensitive metabolic organs, 
including adipose tissue, liver and muscle, and their interaction with the brain. 
One of the principle targets of insulin is the adipocytes. Insulin promotes the storage of excess 
glucose, and its conversion to fat, leading to increased adiposity; a major risk factor for the 
development of metabolic disease. Several groups have demonstrated that adipose tissue 
produces H2S, and that gasotransmitter production and signaling in the adipocytes is altered 
during obesity. Feng and colleagues were the first group to describe the expression of CBS and 
CSE, and production of H2S from rat adipocytes (130). In this report they demonstrated that H2S 
impairs insulin mediated glucose uptake, and that high fructose-induced diabetes led to increased 
production of H2S in epididymal adipose tissue; an effect that could be blocked by inhibiting 
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CSE. This result points toward a negative effect of H2S on glucose metabolism in the adipocytes. 
Interestingly, circulating levels of H2S are lower in obese humans (101), suggesting a disconnect 
between the increased production observed in the rodent adipose tissue. Some groups have 
demonstrated a positive role for H2S in glucose metabolism in the adipocytes. One study in 
3T3L1 adipocytes found that H2S is required for vitamin D induced GLUT4 translocation and 
glucose uptake (131). Another positive role for H2S in adipose tissue metabolism appears to be 
its role in reducing inflammatory cytokine production from resident adipose macrophages. These 
cytokines are a known causal factors in the development of insulin resistance in adipose and 
other metabolic tissues  (132).  In one study, macrophages isolated from mice with diet-induced 
obesity produced less H2S and more cytokines than macrophages from lean mice (103). Based on 
these reports, it may be important that future work in adipose tissue (from obese subjects) 
separate the adipocytes from the stromal vascular fraction.  Several studies have also shown a 
role for the H2S /CSE system in perivascular adipose tissue, although most of this work has 
described its importance in vascular tone (reviewed in  (133)) rather than glucose homeostasis.   
Another key organ in the regulation of glucose metabolism is the liver. During an elevated 
circulating glucose scenario, insulin acts on the liver to stimulate glucose uptake and its 
conversion to glycogen and fatty acids for storage. In a low glucose scenario, pancreatic 
glucagon acts on the liver to promote the production or liberation of glucose through 
gluconeogenesis or glycogenolysis, respectively. Dysregulation of insulin signaling in the liver 
(hepatic insulin resistance) is a common phenomenon in T2DM (reviewed in  (134)). The mRNA 
expression of both CSE and CBS was demonstrated in the liver of rats, and was found to increase 
after inducing type 1 diabetes with Streptozotocin (STZ) (102). Later on it was demonstrated that 
overexpressing CSE in hepatocytes leads to reduced glycogen content. In this study, it was also 
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shown that CSE KO animals (lower H2S) have a reduction in endogenous glucose production 
(135). A recent study by Ju and colleagues demonstrated a mechanism by which H2S may 
directly stimulate gluconeogenesis. They found that pyruvate carboxylase (a key enzyme in 
gluconeogenesis) is sulfhydrated by H2S, which leads to increased activity and glucose 
production  (107). These findings seem to indicate that H2S production in the liver causes 
enhanced glucose release, an effect that would aggravate the hyperglycemia observed in 
diabetes. 
Surprisingly, there is a paucity of studies that have examined the role of H2S in skeletal muscle, 
let alone, skeletal muscle glucose uptake. This may be due in part to the low, or non-detectable 
levels of the H2S producing enzymes in rodent models (in contrast to the higher levels found in 
human muscle, reviewed in (136). Nevertheless, future work should, at the very least, examine 
the effects of H2S donors since H2S may act on muscle tissue via its circulating stores.   
 
Other hormones and future work 
While H2S plays important roles in the metabolism of hormones like insulin and glucagon, a 
variety of other metabolic hormones remain to be examined. One emerging area holding 
potential for this is the gastrointestinal endocrine system. Here, a variety of enteroendocrine cells 
secrete numerous peptide hormones that play important roles in glucose homeostasis and energy 
metabolism. Some important candidates are the insulin-stimulating incretin hormones; glucose-
dependent insulinotropic polypeptide (GIP) and glucagon like peptide-1 (GLP-1). Recently, Bala 
and colleagues examined the role of endogenous H2S in a GI endocrine cell line, STC-1  (137). 
This cell line secretes the GLP-1 and the anorexic hormone peptide YY (PYY). They found that 
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H2S donors and L-cysteine impaired oleic acid stimulated GLP-1 and PYY secretion. While their 
primary focus was on the modulatory effect of H2S on oleic acid stimulated hormone secretion, 
their results support that further investigation of the H2S on GI hormone secretion and signaling 
is warranted. Do GI endocrine cells produce their own H2S, and is the altered H2S level observed 
in obesity responsible for the dysregulation in GI hormone secretion (138)? Of importance, GLP-
1 therapies have become a major tool in the treatment of type 2 diabetes  (139)  and recently 
obesity (140). Therefore, the role H2S has in GLP-1 and other endocrine cells may be an 
additional mechanism by which this gasotransmitter can regulate glucose homeostasis.   
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Abstract   
Recently, the gastrointestinal (GI) microbiome, and its metabolites, has emerged as a potential 
regulator of host metabolism. However, to date little is known on the precise mechanisms of how 
this regulation occurs. Hydrogen sulfide (H2S) is abundantly produced in the colon by sulfate-
reducing bacteria (SRB). H2S is a bioactive gas that plays regulatory roles in many systems 
including metabolic hormone regulation. Importantly, this gas metabolite is produced in close 
proximity to the glucagon like peptide-1 (GLP-1) secreting cells in the gut epithelium. GLP-1 is 
a peptide hormone that plays pivotal roles in both glucose homeostasis and appetite regulation. 
We hypothesized that H2S can directly regulate GLP-1 secretion. We first demonstrated that H2S 
donors (NaHS and GYY4137) directly stimulate GLP-1 secretion in murine L-cells (GLUTag) 
and that this occurs through p38 MAPK without affecting cell viability. We then increased SRB 
in mice by administering a prebiotic chondroitin sulfate containing diet for 4 weeks. Chondroitin 
sulfate treated mice had elevated Desulfovibrio piger levels in the feces and increased colonic 
H2S concentration. Chondroitin sulfate treated animals also had enhanced GLP-1 secretion, 
improved oral glucose tolerance, and reduced food consumption. These results indicate that H2S 
plays a stimulatory role in GLP-1 secretion, and that sulfate prebiotics can enhance GLP-1 
release and its downstream metabolic actions. 
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Introduction  
Obesity, and its associated metabolic co-morbidities including cardiovascular disease, type 2 
diabetes mellitus (T2DM), nonalcoholic fatty liver disease, and others (73), continue to affect a 
growing proportion of the world.  A recently approved treatment in both T2DM and obesity are 
incretin based therapies. These gastrointestinal hormones, including glucagon-like peptide-1 
(GLP-1), are released from enteroendocrine cells in the GI tract and regulate many of our 
metabolic functions such as appetite, glucose homeostasis, and gastric motility, reviewed in 141–
144. Due to its appetite suppressing and insulinotropic actions,  GLP-1 based therapies are now 
an attractive non-insulinic options for patients with T2DM (58,60,145) and morbid obesity (7, 9).  
In the last decade, the gastrointestinal microbiome has emerged as a potential regulator of overall 
metabolism. Metabolic disorders such as obesity and T2DM have been closely linked with 
changes in gut microbiota (147–149). Indeed, the gut microbiome has the ability, when 
transplanted, to alter energy homeostasis and weight gain (150). Importantly, interactions 
between the gut microflora and the enteroendocrine system have been recently demonstrated. 
Short-chain fatty acids (SCFAs), end products of intestinal bacterial fermentation, significantly 
increase the release of postprandial plasma GLP-1 in humans and mice (151,152). Indole, an end 
product of bacterial tryptophan breakdown, stimulates GLP-1 secretion in acute treatments in 
vitro (153). Many other bacterial metabolites are present in the gut from colonic microbial 
metabolism, including polyphenols, secondary bile acids, and sulfur compounds (91); however, 
relatively little is known of the interaction of these bacterial metabolites and the local 
enteroendocrine cells of the GI tract.  
Hydrogen sulfide (H2S) is a bacterial metabolite that is produced by sulfate-reducing bacteria 
(SRB) in the colon, and endogenously in many mammalian cell types. The endogenous 
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production of H2S (in nanomolar amounts)  is known as an essential signal transmitting 
molecule, termed “gasotransmitter”, that acts on a variety of systems including cardiovascular, 
nervous, muscular, and  endocrine (99,154,155). Of key importance, millimolar concentrations 
of microbial H2S can be found within the lumen of the colon (99,116,156). This environment 
also contains the highest proportion of GLP-1 secreting L-cells (38). Despite this proximity, and 
the known role of H2S as an endocrine modulator, very little is understood regarding the 
potential crosstalk between the H2S and GLP-1. The goal of this study was to investigate the role 
of H2S in the regulation of GLP-1. In vitro, this was done directly by using H2S donors on the 
murine GLP-1 secreting GLUTag cell line. In vivo, a previously validated SRB prebiotic diet 
containing chondroitin sulfate was used to increase SRB and H2S production. GLP-1 secretion, 
food consumption, and glucose tolerance were then examined in mice with enhanced SRB and 
H2S levels.  
 
Materials and methods 
Animals 
Experiments were performed following the guidelines outlined by the Canadian Council on 
Animal Care guide to the Care and Use of Experimental Animals (CCAC, Ottawa, ON: Vol. 1, 
2nd edition, 1993: Vol. 2, 1984). Animal protocols were approved by the Laurentian University 
Animal Care Committee. Male wild-type C57BL/6 mice aged 5-6 weeks were purchased from 
Charles River Laboratories (St. Constant, Quebec) and singly housed in standard cages on a 12-h 
light/dark cycle in the Paul Field Animal Care Facility at Laurentian University.   
Diet and study design 
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Following a week-long acclimatization period on chow diet, 26 male mice were randomly 
divided into two groups. Animals were fed a diet ad libitum low in fermentable carbohydrates 
(20% wt/wt fat and 47% wt/wt sucrose) with or without chondroitin sulfate (3% wt/wt) for 4 
weeks (custom diet prepared by Envigo Teklad Diets, Madison WI) as previously done (157). 
Animals had access to water ad libitum. Body weight and food intake were recorded daily and 
fecal material was collected and snap frozen every 2 days. Blood was collected every two weeks 
after an oral glucose gavage (OGTT) for glucose and GLP-1 measurements.  
Once the study was complete, the mice were anesthetized with 5% isoflurane (500-1000 ml/min) 
until the animal was unresponsive to toe pinch, as per Animal Care approved Protocol. Cardiac 
puncture was performed to retrieve up to 1 ml of blood. Cervical dislocation was done as a 
secondary method of euthanasia to ensure animal is deceased.  
Oral glucose tolerance test (OGTT) 
An oral glucose tolerance test (OGTT) was performed at 0, 2, and 4 weeks of the study. 
Overnight-fasted mice received an oral gavage of D-(+)-glucose (2g/kg body wt). A small 
incision was made at the distal end of the lateral tail vein and blood was collected into EDTA 
coated capillary tubes for GLP-1 measurements at 0, 10, and 60 min after glucose gavage (158). 
An aprotinin (protease inhibitor), diprotin A (DPP-4 inhibitor), and additional EDTA cocktail 
were supplemented to the capillary tubes (10% v/v) to prevent degradation of the target 
hormone. Blood glucose was measured during the experiment using a glucometer (OneTouch 
Verio) at 0, 10, 60, and 90 min after glucose administration. 
GLP-1 analysis 
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Blood samples were collected and kept in ice from the OGTT experiment. Approximately 60 uL 
of whole blood was centrifuged at 6000*g for 10 minutes at 4°C. 25uL of plasma was examined 
for total GLP-1 using a commercial competitive ELISA kit (Sigma Aldrich, St-Louis, MO).  
Fecal microbe genomic analysis  
Fecal material was collected from the mice by grasping the skin around the neck and positioning 
the mouse upright until a fecal pellet was excreted directly into the DNA extraction tube, or by 
placing the animal in a clean cage and collecting the fecal sample with sterile forceps. 
Approximately 2-5 stool pellets were collected per mouse per collection period (~40 – 100mg). 
After collection, samples were stored at -80 °C until analysis. Genomic DNA was extracted from 
equal fecal weight (30mg) samples using FavorPrep™ Stool DNA Isolation Mini Kit as directed 
by the manufacturer (Favorogen Biotech Corporation), and the DNA samples were eluted into 50 
uL aliquots. The concentration and purity of the resulting DNA was determined by 260 and 280 
nm spectrophotometry and stored at -20°C. 
Targeted real-time PCR 
Fecal DNA was examined for Desulfovibrio piger (D. piger) and total bacterial genomic DNA 
(16S). The previously validated D. piger primer sequence originated from Rey et al.: 
DpigGOR1_fwd 5’ -AAAGGAAGCACCGGCTAACT-3′, DpigGOR1_rev 5′-
CGGATTCAAGTCGTGCAGTA- 3′ (45). A previously validated bacterial universal 16S rRNA 
gene primer was acquired from Ritz et al.: 1048F 5’ – GTGSTGCAYGGYTGTCGTCA – 3’, 
1194R 5’- ACGTCRTCCMCACCTTCCTC – 3’ (159).  
Quantitative real-time PCR reactions (10 uL) contained 2uL of 10x diluted template DNA (80 ng 
final concentration), 5uL 2X SensiFast SYBR No-ROX supermix (Bioline Inc., Tauton, MA), 
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0.5 uL of forward and reverse primers (500 nM final concentration of each), and 2.5 uL sterile 
H2O. As directed by the manufacturer, PCR was comprised of an initial denaturation step of 
95°C for 1 min, followed by 40 cycles of 95°C for 15s, 55°C for 15s, and 72°C for 15s. PCR 
controls included a no-template control (NTC) reaction, replacing the template with PCR grade 
water. PCR standards were made from gel quantified PCR products for D. Piger. Standards, 
samples, and NTCs were run in triplicates, and CT values were averaged. Quantification was 
completed using the standard curve method with D. piger being normalized to total bacteria 
(ribosomal 16s).  
Hydrogen sulfide measurement 
Fecal and colonic content hydrogen sulfide levels were quantified using the methylene blue 
method (160). Colonic contents were collected post-sacrifice. The material (~0.1g) was 
homogenized with 1% Zinc acetate trapping solution, 20 mM N,N-dimethyl-p-phenylenediamine 
sulfate in 7.2 N HCl, 30 mM FeCL3 in 1.2 N HCl, and incubated for 30 min. Samples were 
centrifuged, and the clear upper phase was analyzed at 670 nm in comparison to a calibration 
curve of standard H2S solutions (161,162). H2S levels were expressed in µM/gram wet weight of 
feces or colonic contents. 
Cell culture and GLP-1 Secretion 
Mouse GLP-1 secreting GLUTag cells (Passage 10-30; a kind contribution from Dr. Drucker, 
Lunenfeld-Tanenbaum Research Institute, Toronto, ON) were grown as previously described by 
Gil-Lozano and Brubaker (163). GLUTag cells were seeded in 6-well plates (1,000,000 cells per 
well) and received treatment upon reaching approximately 80% confluence after 48 hours. Cells 
were treated for 2 hours (164) with H2S donors: sodium hydrosulfide (NaHS; Fisher Scientific, 
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Mississauga Ontario) or GYY4137 (Cayman Chemicals, Ann Armor, MI), dissolved in low 
serum DMEM (0.5% FBS; GE Healthcare Life Sciences). Media with vehicle (water for NaHS 
experiment, DMSO for GYY4137 experiment) served as a control for baseline secretion, and 
forskolin was used as a positive control for GLP-1 secretion (data not shown). Total cellular 
protein content was assayed using the Bradford method, and no differences were observed (data 
not shown).  Following the incubation, the collected media was acidified using trifluoroacetic 
acid to a final concentration of 0.1% and purified through a Sep-Pak C18 as per manufacturers’ 
instructions (Waters, Germany). The retained material was eluted with 80% Isopropanol, 0.1% 
TFA, and then dried down using the Integrated Speedvac System. The dried purified samples 
were stored at -20°C until analysis. A commercial total GLP-1 competitive ELISA kit (Sigma 
Aldrich, St-Louis, MO) was used to quantify GLP-1 levels from dried samples.  
Under similar experimental conditions, cell viability was determined by neutral red uptake assay, 
as described by (165). This technique is based on the ability of viable cells to incorporate neutral 
red dye in the lysosomes, after the cells have been treated with NaHS, GYY4137, or control 
media. 
Western blot  
GLUTag cells were seeded into 6-well plates for 48 hours. Cells were treated for 10 min in 
serum free media containing vehicle or an H2S donor. Cells were lysed in lysis buffer (Cell 
Signaling Technologies, Danvers, MA Technologies) containing a phosphatase inhibitor 
(PhosphoSTOP by Roche), and a protease inhibitor (EDTA Free CompleteMini by Roche). 
Protein content was quantified by Bradford method (50 µg protein per well loaded) separated on 
an 8% denaturing SDS-PAGE Tris-glycine gel, transferred to a polyvinylidene fluoride (PVDF) 
membrane, blocked with 5% skim milk in Tris-buffered saline, and incubated overnight at 4°C 
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with the primary polyclonal rabbit antibody (phosphor- or total- p38 MAP kinase; Cell Signaling 
Technologies, Danvers MA). After washing in TBS, the membrane was incubated for 2 hours at 
room temperature with horseradish peroxidase-conjugated anti-rabbit secondary antibody (Cell 
Signaling Technologies, Danvers, MA). The proteins were visualized using a Luminata Forte 
chemiluminescence HRP substrate (Millipore Corp, Billerica, MA), and luminescence was 
detected using the BioRad chemi doc XRS system (for antibodies, see Table 2). Total cognate 
antibodies (AKT and p38 MAPK) were used as an internal loading control by dividing the ratio 
of phospho-protein levels by the total protein levels. The phospho/total ratios of treated sampled 
were compared to those of the untreated samples to create the figures annotated “Relative to 
Control”.   
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Table 2. List of antibodies 
 
Peptide/Protein 
Target 
Antigen 
Sequence 
Name of 
Antibody 
Manufacturer Species 
Raised in; 
Monoclonal 
or 
Polyclonal 
Dilution 
Used 
RRID 
Phosphor-p38 
MAP kinase 
T180/Y182 Phosphor-
p38 
MAPK 
Cell Signaling 
Technologies 
Rabbit; 
polyclonal 
1:1000 AB_10080263 
P38 MAP 
Kinase 
 P38 
MAPK 
Cell Signaling 
Technologies 
Rabbit; 
polyclonal 
1:1000 AB_2225340 
Phosphor-AKT S-473 Phosphor-
AKT 
Cell Signaling 
Technologies 
Rabbit; 
polyclonal 
1:1000 AB_330713 
AKT pan   AKT Cell Signaling 
Technologies 
Rabbit; 
polyclonal 
1:1000 AB_2315049 
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Statistical analysis 
All data are expressed as mean ± SEM. All measures were tested for normality; sets that passed 
the normality test were assessed using parametric techniques. Studies comparing 2 groups were 
analyzed by Student’s t-test. Studies with multiple doses of the same treatment were analyzed by 
one-way ANOVA, followed by a Bonferroni post hoc test. Studies with 2 or more independent 
variables (i.e., time and treatment doses) were analyzed by two-way ANOVA, followed by 
Bonferroni post hoc tests at individual time points where applicable. P <0.05 was considered 
significant.  
 
Results 
H2S donors stimulate GLP-1 secretion in vitro 
To determine the direct effect of H2S on GLP-1 secretion, GLUTag cells were treated with an 
H2S donor (NaHS or GYY4137), or control media for 2 hr. Sodium hydrosulfide (NaHS) 
increased GLP-1 secretion (P < 0.05 one-way ANOVA), with the highest dose of NaHS (10 
mM) causing a 1.98 ± 0.2 fold increase (Fig. 3A). Lower doses of GYY4137 also caused a 
significant increase of GLP-1 levels (P < 0.05 one-way ANOVA), with the highest dose of 
GYY4137 (100uM) producing a 2.2 ± 0.21 fold increase of GLP-1 (Fig. 3B). All H2S treatments 
used did not reduce cell viability, as shown by the neutral red assay (Fig. 3C).  
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 Figure 3. Effects of H2S on GLP-1 secretion and cell viability in GLUTag cells. 
GLP-1 secretion was analyzed in media from cells treated with NaHS (A) or GYY4137 (B) for 2 
hours. Cell viability was examined under similar conditions (C). Data is presented relative to 
vehicle control with the absolute values from control in inset 3A. n=6-9; * = P < 0.05 vs. control 
cells; *** = P < 0.001 vs control cells. 
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P38 MAPK is involved in H2S-stimulated GLP-1 secretion in vitro 
To determine potential intracellular mechanisms involved in the enhanced GLP-1 secretion by 
H2S, we treated GLUTag cells with the most effective dose of NaHS (10 mM) for 10 min, and 
examined the phosphorylation of p38 MAPK and AKT by Western blot. P38 MAPK 
phosphorylation was significantly increased by 1.61±0.18 fold after treatment (P < 0.05; Fig. 
4B). We did not observe an increase in phosphorylated AKT (Fig. 4A). To confirm the 
importance of p38 MAPK in H2S-stimulated GLP-1 secretion, we co-incubated the p38 MAPK 
inhibitor IV with NaHS. NaHS-stimulated GLP-1 secretion was completely blocked by the 
addition of the kinase inhibitor (Fig. 4C). 
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 Figure 4. Effect of H2S donor (NaHS) on p38 MAPK and AKT phosphorylation in 
GLUTag cells. 
AKT phosphorylation/total AKT was examined in GLUTag cells treated with NaHS (10 mM) 
for 10 min by western blot (A).  P38 MAPK phosphorylation/total p38 MAPK was examined in 
GLUTag cells treated with NaHS (10 mM) for 10 min by western blot (B).  GLP-1 secretion was 
examined in NaHS (0-10mM) treated cells co-incubated with and without the p38 MAPK 
inhibitor IV (50 nM) (C). Data is presented relative to vehicle control. n = 6; *, P < 0.05 vs. 
control cells. 
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Chondroitin sulfate prebiotic diet increases H2S and SRB levels 
To increase the amount of SRB and microbial H2S in vivo, mice were provided with a prebiotic 
diet consisting of a 3% chondroitin sulfate in the presence of a diet low in fermentable 
carbohydrates. Fecal DNA was collected throughout the study and analyzed for the abundance of 
D. piger using targeted qPCR. In comparison to their respective baseline levels, the control 
group had a 3.4 ± 0.33 fold increase of D. piger, and the treatment group had a 4.4 ± 0.26 fold 
increase. Importantly, there was a 1.29 ± 0.07 fold change in treatment vs control D. piger levels 
following the four week diet (P < 0.05 t = Day 28, P < 0.05 for chondroitin sulfate interaction in 
2-way ANOVA; Fig. 5A). Therefore, the prebiotic chondroitin sulfate significantly increased the 
abundance of D. piger. 
To verify that this increase in fecal D. piger levels corresponded with increased levels of H2S, 
the amount of fecal and terminal colon H2S were determined using the methylene blue method. 
The pre-diet intervention levels (in feces) were similar in both control and treatment groups (0.49 
umol/g, Fig. 5B). After the four-week prebiotic diet, fecal and colonic contents were examined 
for H2S. Colonic material was less exposed to oxygen (a factor that causes loss of H2S) and was 
therefore used in the post diet comparison. The treatment group had a 1.50 ± 0.03 fold increase 
of colonic H2S (0.81 μmol/g) compared to control (P < 0.05, Fig. 5C).  
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 Figure 5. The effect of dietary chondroitin sulfate intervention on SRB and H2S levels in 
mice. 
Fecal D. piger levels were examined by qPCR at day 0 and following the 4-week chondroitin 
sulfate diet (A). H2S levels were examined in both groups at the start of the study in feces (B) 
and at the end of the study from colonic contents (C). n = 13 per group; *, P < 0.05 vs control 
animals. 
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Chondroitin sulfate prebiotic diet enhances GLP-1 response, improves oral glucose 
clearance, and reduces feeding 
To determine the effect of the increased SRB and H2S levels on GLP-1 secretion and 
downstream metabolic function, control and prebiotic treated mice were examined after 4 weeks 
of diet intervention. Chondroitin sulfate treated mice had a significant increase in glucose 
stimulated GLP-1 secretion (overall treatment effect compared to control P < 0.05 with post-hoc 
significance at 10 min, P < 0.001; Fig. 6A). Area under the curve for GLP-1 secretion was 
significantly elevated in the prebiotic treated group (1.21 ±0.06 of control, P < 0.05; Fig. 6B). 
Oral glucose tolerance was examined pre- and post- prebiotic diet intervention. Both groups 
began the study with similar glucose tolerance (Data not shown). Following the four week diet 
the chondroitin sulfate group had significantly improved glucose tolerance (overall treatment 
effect compared to control P < 0.01 with post hoc significance at 60 min, P < 0.01; Fig. 6C). 
AUC of glucose was significantly lower in the prebiotic group (0.87 ± 0.05 of control, P < 0.05; 
Fig. 6D). Insulin response was also significantly improved in the chondroitin sulfate group 
(overall treatment effect compared to control P < 0.01; Fig. 6E & 6F). Finally, while differences 
in weight gain were not observed in the time course of this study (data not shown), significant 
reduction in food consumption began to emerge in the treatment group after day 18 (AUC day 
18-28; 0.87±0.06 fold, P < 0.05, Fig. 4G & 4H). 
43 
 
 Figure 6. GLP-1 and metabolic profiles of mice after 4-week prebiotic diet. 
The GLP-1 response to oral glucose was examined in control and chondroitin sulfate treated 
animals (A and B AUC). Delta glucose was examined after OGTT (C and D AUC). Plasma 
insulin was examined after OGTT (E and F AUC). Food consumption was examined in the last 9 
days of the study (G and H AUC).  n = 13 per group; *, P < 0.05 vs control animals. 
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Discussion 
The incretin hormone GLP-1 has become an important therapeutic target in the treatment of 
T2DM and obesity, and novel strategies to increase GLP-1 remain a major research focus. In 
addition, the GI microbiome has recently emerged as a potential player in the regulation of 
metabolic health in part through the production of microbial metabolites. These metabolites 
include H2S, which is an established regulatory gas (gasotransmitter) in several systems. Since 
H2S is already known to regulate certain metabolic hormones, and H2S producing SRB reside in 
the same environment of the GLP-1 secreting L-cells, we aimed to determine if H2S plays a 
regulatory role in GLP-1 secretion and its downstream metabolism.  Our results indicate that H2S 
directly stimulated GLP-1 secretion, and that increasing SRB in mice using a prebiotic diet led to 
enhanced GLP-1 and insulin secretion, improved glucose tolerance, and reduced feeding.    
When examining the direct effect of a secretagogue on GLP-1 secretion, it is important to 
demonstrate the effect using a treatment concentration within the physiological range. In our in 
vitro work, H2S donors were used in the µM to mM range. While these H2S  donors liberate the 
gas in different manners, the concentration of gas produced over the 2 hours are expected to be 
within the range of luminal concentrations of H2S produced through microbial respiration 
(99,116,166). This is in contrast to the nM concentrations of H2S that are produced endogenously 
from the colonic epithelium (167). To estimate the quantity of H2S that is present within the 
colon, mouse colonic content H2S was determined. Once again, these concentrations were found 
to be within the uM range (umol/gram wet weight) and are in line with other work examining 
fecal H2S concentrations (between 0.29 umol/g – 1.6 umol/g (168–171)).   
We also found that the H2S stimulation of GLP-1 secretion occurred through the P38 mitogen-
activated protein kinase (p38 MAPK). This is of particular importance since H2S is not known to 
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have a cell based receptor, and the mechanism of H2S action remains an active area of research. 
However, our finding that p38 MAPK is mechanistically involved is in agreement with other 
studies that have examined the mechanism of H2S action in other systems (105,172,173). 
Importantly, Reimer and colleagues have demonstrated a role for p38 MAPK phosphorylation in 
the secretion of GLP-1 (174). Combined, these works support a role for H2S mediated activation 
of p38 MAPK as the signaling mechanism for enhanced GLP-1 secretion. 
Our finding that H2S stimulates GLP-1 secretion appears to be in contrast to a recent study by 
Bala and colleagues (175). They demonstrated that H2S inhibits oleanolic-acid stimulated GLP-1 
secretion in the STC-1 cell line. There are however several important differences between our 
and Bala et al. cell culture experiments.  Mainly, their study uses the secretin tumor cell line, 
STC-1. While this cell line produces and secretes GLP-1, it is derived from the small intestine 
(176), and may have alternate regulation compared to the colonic derived GLUTag cell line. 
Since SRB require the anaerobic environment of the colon, microbial H2S concentrations (in the 
uM-mM range) would likely not be present in the upper small intestine.  Therefore, it is possible 
that the STC-1 from the small intestine, and the GLUTag cells from the colon, use different 
pathways and react differently to H2S stimuli. Nevertheless, findings from cell culture studies in 
tumor cell lines should be confirmed with an in vivo model as was completed here. 
Supplementing the diet with the sulfated glycosaminoglycan, chondroitin sulfate, led to an 
increase in SRB compared to control.  This compound was selected because unlike other sulfate  
molecules that are quickly absorbed by the gut, glycan-bound sulfate (such as chondroitin 
sulfate) is poorly absorbed in the small intestine (177), and is more likely to liberate the sulfate in 
the distal GI tract where it can be used by SRB for H2S production. Similar to Rey and 
colleagues, we observed an increase in the abundance of D. piger  and H2S levels in mice on 
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chondroitin sulfate diet (157). However, our levels of D. piger community abundance were lower 
than in Rey’s study. This is likely due to their mice being germ free and inoculated with an 8 
species defined microbiome community including D. piger. Interestingly, control mice in our 
study also had an increase in SRB after 4 weeks. This is likely due to the low fermentable 
carbohydrate diet, which enhances the use of host derived sulfated glycans in the lumen, to be 
natural substrate used by SRB (157). Nevertheless, supplementing additional sulfate in the 
treatment group with chondroitin sulfate further enhanced the SRB levels.  Interestingly, only the 
chondroitin sulfate treated mice had increased levels of H2S, which suggests additional sulfur 
substrates are required to increase H2S production. 
In agreement with our in vitro work, the chondroitin sulfate treated mice (which exhibited higher 
levels of colonic H2S) had a significant improvement in their GLP-1 response. However, this 
difference was observed only after oral glucose administration and not at the baseline (time 0). 
What may be happening in the H2S enriched in vivo environment is a “priming” of the L-cell in 
preparation for subsequent glucose-stimulated GLP-1 secretion. Indeed, endocrine cell priming 
has been previously described in other cells such as β-cells and ghrelin cells (178,179). Along 
with increased GLP-1 secretion, we observed an improved glucose tolerance and reduced food 
consumption in the chondroitin sulfate animals. The latter became apparent in last 9 days of the 
study, indicating that there was no initial taste aversion to the chondroitin sulfate. These findings 
are in agreement with GLP-1’s established role in mediating increased insulin stimulation and 
satiety (180). Surprisingly, we did not observe a significant weight difference during the course 
of this study. However, this may be due to the short duration of this study (4 weeks). Future 
studies may examine long term weight changes or weight loss interventions to fully elucidate the 
role of H2S in body weight regulation. In addition, future use of germ free mice given a SRB 
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probiotic, and a diet-reversal period, would strengthen the relationship between microbial H2S 
production and enhanced GLP-1 secretion.  
In summary, we have demonstrated a role for H2S in the stimulation of GLP-1 secretion. This 
effect was shown directly in L-cells and indirectly through prebiotic enhancement of the SRB 
community. These results provide some of the first evidence of how microbial gases are able to 
influence gut endocrine system and downstream metabolism. 
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3.  Extended Discussion 
3.1 Clinical implications of prebiotics, probiotics, and H2S-releasing agents 
As summarized by (181), there are many studies that confirm the beneficial use of probiotics and 
prebiotics in humans and rodents. Probiotics contain a live microbial supplement, and are orally 
ingested to alter the gut microflora of the host (Reviewed in (182)). On the other hand, prebiotics 
are non-living supplements, containing non-digestible dietary components which selectively help 
the proliferation and/or activity of certain gut bacteria (Reviewed in (183)). These studies 
demonstrate that the beneficial effects from prebiotics or probiotics can occur as early as 2 weeks 
to 8 weeks (181). In the context of glucose homeostasis, a few yogurt-based probiotics 
containing Lactobacillus and Bifidobacteria (carbohydrate fermenters) have been shown to 
reduce fasting glucose, and delay the progression of glucose intolerance and hyperglycemia in 
diabetic rats (184) and humans (185). Prebiotics containing non-digestible carbohydrates have 
also been shown to improve glycaemia and insulimia of patients with T2DM (186–188). 
Therefore, prebiotics and probiotics are possible tools to modulate the gut microbiota for the 
management of T2DM.  
The use of chondroitin sulfate has been seen mainly as a supplement for patients with 
osteoarthritis (OA), atherosclerosis, IBD, degenerative diseases, and other autoimmune diseases, 
and has been shown to have many anti-inflammatory properties, as reviewed in (189). 
Chondroitin sulfate was used in this study to increase the growth of SRB, and thus the levels of 
colonic H2S (189). H2S also has anti-inflammatory and cytoprotective properties as previously 
discussed. Clinical trials are underway to examine H2S-releasing agents in combination with 
non-steroidal anti-inflammatory drugs (NSAIDs), used to reduce pain and inflammation 
(Reviewed in (190)). In these trials, H2S is added to reduce the gastric injury that occurs as a side 
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effect of the NSAID (191–194). Therefore, the beneficial use of H2S in drugs is well established 
in that category.  
The rationale behind using chondroitin sulfate as opposed to another sulfur-donor is that many 
H2S donors are partially, if not fully, absorbed in the stomach and intestine before it reaches the 
colon. The fermenting and sulfate-reducing bacteria that work together to create H2S from 
chondroitin sulfate are more abundant in the distal small intestine and colon. Therefore, we 
suggest this could be a novel method to produce H2S at a steady rate in the lower GI tract 
without it being absorbed in other regions of the GI tract. The established safety profile and other 
health benefits of chondroitin sulfate, along with the established anti-
inflammatory/cytoprotective properties of H2S, make chondroitin sulfate an attractive compound 
to explore in future research regarding colon health.  
As shown in Chapter 2, we have established that H2S production and a marker species of SRB 
are increased with the chondroitin sulfate prebiotic diet. This resulted in an increase of GLP-1 
secretion from the colonic L-cells and subsequent glycemic benefits. The mechanism of H2S’s 
action on GLP-1 secretion and the L-cell will now be discussed.  
3.2 Molecular mechanisms of H2S action on GLP-1 secretory pathway  
H2S remains a mystery as to what molecular pathways are being activated, due to the lack of a 
known cellular receptor. In various tissues where H2S’s action was studied, a few mechanisms 
have been proposed. Some reports have suggested that H2S modifies proteins, including ion 
channels and enzymes by interacting with the cysteine residues through a process called 
persulfhydration (126). Persulfhydration occurs when a sulfur group from H2S is added to a thiol 
group of a cysteine residue. This reaction yields a hydropersulfide (-SSH), which has been 
shown to increase the biological activity and reactivity of a protein or enzyme. For example, the 
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activity of glyceraldehyde 3-phosphate dehydrogenase (GAPDH), an enzyme involved in 
glycolysis and other cellular processes, is greatly increased when sulfhydrated (126). Whether 
sulfhydration has a similar effect in other enzymes is an active field of research.  
In my work I demonstrated that NaHS causes an increase in the phosphorylation of the p38 
mitogen activated protein kinase (MAPK) and that blocking this kinase prevents the action of 
NaHS. The MAPK family is known to be involved in cell proliferation, differentiation, and 
apoptosis (195). Importantly, the p38 MAPK is also known to play a role in GLP-1 regulation. 
Several groups have demonstrated the activation of this kinase during GLP-1 secretion 
(174,196). The literature surrounding the effect of H2S in p38 MAPK activation is conflicting, 
likely due to different cell models and methodology. NaHS upregulates p38 MAPK in human 
cultured umbilical vein endothelial cells (197) and gastric mucosal epithelial cells (198), 
however inhibits this kinase in human polymorphonuclear leukocytes (199), and cultured rat 
aortic vascular smooth muscle cells (200). P38 MAPK has several downstream targets, including 
many transcription factors and protein kinases. Changes in gene expression of proglucagon or 
proprotein convertases are likely not to have occurred during the 2 hour incubation of our in vitro 
experiments. P38 MAPK has been previously shown to be involved in the exocytosis of 
secretory vesicles of human neutrophils and microglial cells, although the direct targets and 
downstream mechanisms are unknown (201,202). It is possible that the enhancement (or 
inhibition of by p38 MAPK inhibitor IV) of p38 MAPK is involved in mediating the exocytosis 
of the GLP-1 vesicles. The area of research involving p38 MAPK and vesicle exocytosis, and the 
exocytotic mechanisms of GLP-1 release are understudied and require further examination to 
conclude the role of this kinase.  
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We also examined the activation of protein kinase B (AKT) in vitro. This is another kinase 
involved in proliferation, differentiation, and apoptosis (203). Interestingly, the AKT pathway is 
a known target of H2S. H2S stimulates AKT phosphorylation in cultured endothelial cells (204), 
ischemic hind-limb muscles in rats (205), and colon cancer cells (206) . In the context of the 
GLP-1 secretory pathway, AKT is also known to be phosphorylated in insulin-induced GLP-1 
secretion (207). However, in this study we did not see an activation of AKT by H2S. It is 
possible that AKT is phosphorylated at a time point we have not examined, or that simply H2S 
does not induce the phosphorylation of the AKT pathway in this cell line.  
Another interesting kinase to examine could be the extracellular signal-regulated kinase (ERK) 
1/2. This kinase is an established H2S target in a few cell models (206,208,209). ERK 1/2  is also 
involved in GLP-1 secretion, as seen in its activation during meat hydrosylate-stimulated (174) 
and insulin-induced GLP-1 secretion (207).  
As described in the review in chapter 1, H2S has been shown to open KATP channels and close 
calcium channels. However, the closure of the KATP channel and the opening of the calcium 
channel are involved in potentiating the release of GLP-1 vesicles. Since we observed an 
enhanced stimulation of GLP-1, it would be interesting to observe how these channels are altered 
by H2S. Therefore these pathways and other H2S targets could be subject to future examination 
in the L-cell to map out the detailed mechanism as to how H2S stimulates GLP-1 secretion.   
3.4 Microbial H2S: Future perspectives 
The goal of this study was to investigate the role of colonic microbial H2S on the neighbouring 
GLP-1 secreting cells. Although we have demonstrated an important correlation between the 
increases of SRB, fecal and colonic H2S, and increases in GLP-1, there is still further 
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investigation warranted between SRB and GLP-1. To add depth to this study and significantly 
highlight the role of SRB/microbial H2S production and GLP-1, it would be interesting to 
examine our research question through manipulating the SRB microbiota in several manners. 
The use of antibiotics to neutralize the SRB could be cost-effective and simple design, however 
multiple studies have noted that SRB are extremely resistant to most antibiotics (210,211), and 
antibiotics would most likely not eliminate all traces of SRB. GF mice are also frequently used 
as models to study the importance of the microbiota. Microbial H2S studies have used GF mice 
before to differentiate microbial vs endogenous production of H2S (117). However, GF mice also 
have higher levels of GLP-1 due to undigested bile acids arriving to the colon and stimulating the 
L-cells (212). Therefore, this would also not be the ideal model to observe a marked stimulation 
of GLP-1. An ideal system for future work would be the use of gnotobiotic mice. Gnotobiotic 
mice are GF mice inoculated with a defined assemblage of bacterial species. This gnotobiotic 
microflora could be with or in absence of Desulfovibrio piger, to study the direct relationship 
between SRB/ H2S and GLP-1. In the absence of D. piger, chondroitin sulfate should still be 
metabolized into simple sugars and sulfate; however the production of hydrogen sulfide would 
be very limited in the absence of any bacteria capable of using the dissimilatory sulfate reduction 
pathway. It is also possible to inoculate the mice with modified bacteria lacking sulfatase 
enzymes to completely rule out the involvement of sulfate. Taken together, these additional 
studies would strengthen our conclusions that it is indeed microbial H2S that is responsible for 
evoking changes in GLP-1 secretion. 
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4. Conclusions 
H2S is a gasotransmitter that has been studied extensively in several biological systems; 
however, an important missing link is the enteroendocrine system. GLP-1, among the many 
peptides secreted from the enteroendocrine system, is responsible for glucose-dependent insulin 
secretion, delayed gastric emptying, and inducing satiety. In this body of work, we were able to 
show a potential regulatory role for H2S (a microbial metabolite from SRB) on GLP-1 secretion. 
We’ve demonstrated that H2S donors can directly stimulate GLP-1 secretion without reducing 
cell viability in vitro, and that p38 MAPK is an important pathway mitigating this effect. In vivo, 
we were able to successfully elevate SRB and colonic H2S levels using a chondroitin sulfate 
prebiotic. These animals exhibited a reduction in food intake, and an improvement of GLP-
1/insulin response and glucose clearance after a glucose challenge. A greater understanding of 
the crosstalk between microbial metabolites and GI hormones like GLP-1 will enable and foster 
new research into potential therapies using H2S for the management of T2DM. 
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